Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SOLIGENIX, INC. (SNGX)

Soligenix Gets Nasdaq Bid Price Notice, Ends HyBryte Program After Futility Finding

Negative Impact 5 of 5 restructuring Written later

Soligenix received a Nasdaq notice on June 10, 2026 that its stock has failed the $1.00 minimum bid price requirement, with until December 7, 2026 to regain compliance. The company also ended its HyBryte development program after an interim analysis recommended halting the Phase 3 FLASH2 trial for futility, a move that carries estimated wind-down charges of about $70,000.

Key points

  • Nasdaq notice dated June 10, 2026; the stock stays listed on the Nasdaq Capital Market under SNGX for now.
  • Compliance deadline is December 7, 2026, 180 calendar days; a second 180-day period may be available under certain conditions.
  • Board terminated the HyBryte development program on June 11, 2026; wind-down charges estimated at approximately $70,000.
  • Consulting Chief Medical Officer Richard Straube ceased that role on June 11, 2026; duties move to Medical Director Christopher Pullion.

The filing

CompanySOLIGENIX, INC. (SNGX)
Form8-K, current report
Filed with the SECJun 12, 2026, 4:05 PM ET
Accession number0001104659-26-073430

Items reported: 3.01 Delisting / Listing Rule Notice5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.